Healthcare

SUDA Pharmaceuticals Reformulating Billion-Dollar Drugs for Oral Delivery

Australia’s leading oro-mucosal drug delivery company, SUDA Pharmaceuticals Ltd (ASX: SUD) produces reliable oral sprays by using its proprietary OroMist® technology to redevelop the...
NEU

Zooming Lens on Neuren’s Drug Candidate, NNZ-2591

Australian-headquartered biopharmaceutical company, Neuren Pharmaceuticals Limited (ASX: NEU) develops a range of novel therapies for treating neurodevelopmental disorders with a high unmet medical need,...
ResApp Health Acquires CE Mark Certification For World’s First Smartphone-Based Tool For Acute Respiratory Disease

ResApp Health Acquires CE Mark Certification For World’s First Smartphone-Based Tool For Acute Respiratory...

ResApp Health Limited (ASX: RAP), is a prime healthcare company headquartered in Brisbane, Australia that creates clinically validated, regulatory-cleared, smartphone applications based digital tools...

Noxopharm pre-clinical evidence confirms Veyonda® abscopal effect; NOX completes three years on ASX

On 21 August 2019, clinical-stage drug development company Noxopharm Limited (ASX: NOX) pre-clinical evidence confirmed that its lead drug candidate Veyonda® has the potential...

New Generation Healthcare Stocks To Look For- RAC, BOT, AVE, JHL, GLH, LSH

Digital healthcare service has evolved as one of the fastest-growing industries in the modern era. Introduction of technology in medical science has emerged as...

SUDA Makes Speedy Progress with its Robust Product Pipeline

SUDA Pharmaceuticals Ltd (ASX: SUD) is transforming the drug delivery technology to improve the lifestyle and health of the global community by offering innovative...

A Deep Dive into Imugene’s Opportunities in the Immuno-oncology Market

Imugene Limited (ASX: IMU) is a clinical stage biotechnology company that focuses on the development of immunotherapies that have the potential to enable a...

A Lens On Noxopharm’s June 2019 Quarterly Results

Noxopharm Limited (ASX: NOX) has recently released its quarterly report for the three months ended 30 June 2019, covering updates from both Noxopharm and...

Cochlear Limited Unveiled FY19 Results; Reported 7% Revenue Growth

Implantable hearing solutions provider, Cochlear Limited (ASX: COH) has reported a sales revenue growth of 7% in FY19. The company also earned a net...

4 Healthcare Stocks Trading High On ASX- CSL, RMD, RHC, SHL

The below mentioned healthcare stocks are trading close to their 52 weeks high prices. Let’s take a quick look at the recent financial and...

Recent News